Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Lamotrigine in refractory epilepsy].

A García-Escrivà1, N López-Hernández, M Alvarez-Saúco

  • 1Unidad de Epilepsia, Servicio de Neurología, Hospital General Universitario de Alicante, Alicante, España. alescriva@mixmail.com

Revista De Neurologia
|March 5, 2004
PubMed
Summary

Lamotrigine (LTG) effectively controls refractory seizures in many patients. However, a high dropout rate due to side effects or lack of efficacy limits its long-term use in epilepsy management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Status of neurosonology in Spain. A study from the Spanish Society of Neurosonology (SONES).

Neurologia·2025
Same author

Clinicoradiological application of the use of spectral cranial computed tomography in the management of acute ischemic stroke after mechanical thrombectomy.

Revista de neurologia·2024
Same author

The role of vagus nerve stimulation in the treatment of refractory epilepsy: clinical outcomes and impact on quality of life.

Neurologia·2021
Same author

[Alzemon: a prospective follow-up study of eslicarbazepine acetate monotherapy in patients with newly diagnosed epilepsy].

Revista de neurologia·2021
Same author

[Multifocal encephalitis as a neurological manifestation of COVID-19 infection].

Revista de neurologia·2020
Same author

Management of Parkinson's disease and other movement disorders in women of childbearing age: Part 2.

Neurologia·2020

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Lamotrigine (LTG) is an antiepileptic drug for various seizure types.
  • 20-30% of epilepsy patients experience poor seizure control despite treatment.

Purpose of the Study:

  • Evaluate the long-term efficacy and tolerability of lamotrigine in refractory seizures.
  • Assess seizure control, including remission, improvement, and exacerbation.

Main Methods:

  • A 10-year consecutive study of 39 patients with refractory epilepsy treated with LTG.
  • Collected epidemiological and clinical data, including seizure frequency, side effects, and dropout rates.

Main Results:

  • 33% of patients achieved seizure freedom, and 43.6% improved.
  • 18.3% found LTG ineffective, and 5.1% experienced worsening seizures.

Related Experiment Videos

  • Dropout rate was 56.4%, attributed to insufficient seizure control, side effects, or non-compliance.

    • Conclusions:

    • Lamotrigine demonstrates significant efficacy in controlling refractory epilepsy seizures.
    • High dropout rates due to tolerability and compliance issues necessitate careful patient selection and monitoring.